The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial.
 
Vasiliki Pelekanou
No Relationships to Disclose
 
William E. Barlow
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Marie-Kristin von Wahlde
No Relationships to Disclose
 
Brad Wasserman
No Relationships to Disclose
 
Ying-Chun Lo
No Relationships to Disclose
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - Lilly
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Janssen Diagnostics
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - Agendia; Bayer; Celgene; Lilly; Merck; Metastat; Novartis; Peregrine Pharmaceuticals; Roche
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Julie Gralow
Consulting or Advisory Role - Bayer; Genentech; Lilly; Novartis; Pfizer
Research Funding - Amgen (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Debu Tripathy
Consulting or Advisory Role - Nektar; Novartis; Pfizer; Puma Biotechnology
Research Funding - Genentech/Roche (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Robert B. Livingston
No Relationships to Disclose
 
Peggy Porter
No Relationships to Disclose
 
Zeina A. Nahleh
No Relationships to Disclose
 
David L. Rimm
Stock and Other Ownership Interests - Metamark Genetics
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Cell Signaling Technology; Genentech
Consulting or Advisory Role - AstraZeneca; Bethyl Laboratories; Biocept; Bristol-Myers Squibb; Cernostics; Five Prime Therapeutics; Genoptix; Optra SCAN; Perkin Elmer
Research Funding - Cepheid; Gilead Sciences; Kolltan Pharmaceuticals; OncoPlex Diagnostics; Perkin Elmer; Pierre Fabre (Inst)
Patents, Royalties, Other Intellectual Property - Quantitative Immunofluorescence (AQUA) (Inst); Rarecyte Circulating tumor cells
Travel, Accommodations, Expenses - Ventana Medical Systems
 
Lajos Pusztai
Honoraria - BioTheranostics; celgene; Merck; Pfizer
Consulting or Advisory Role - Celgene; Clovis Oncology
Research Funding - Foundation Medicine; Genentech; Merck; Seagen